Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

Table 1 Patient disposition by treatment group.

	Abrupt	Gradual 1	Gradual 2	All treatments
Randomized, n	41	40	42	123
Safety population, n	40	39	42	121
Completed, %	75	72	88	79
Discontinued, %	25	28	12	21
Adverse event	5	15	5	8
Withdrew consent	10	8	0	6
Insufficient response	5	0	0	2
Lost to follow-up	0	3	2	2
Noncompliance	0	0	2	1
Other	5	3	2	2

The safety population includes all randomized patients who received at least one dose of study medication. Between-group discontinuation differences were not significant (p = 0.1635).

ISSN: 1741-7015